We provide you with 20 years of free, institutional-grade data for SGMT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SGMT. Explore the full financial landscape of SGMT stock.
| Reported Date | CIK | Ticker | Type |
|---|
Sagimet Biosciences Inc.(NASDAQ:SGMT) 
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors to treat non-alcoholic steatohepatitis, acne, and various cancers. The company's lead drug candidate is Denifanstat, a fatty acid synthase inhibitor for the treatm...
Share this website to your friends
The information provided in this report about SGMT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.